

39,130, 39,131 (2006); *Dominick A. Ricci, M.D.*, 58 FR 51,104, 51,105 (1993); *Bobby Watts, M.D.*, 53 FR 11,919, 11,920 (1988); *Frederick Marsh Blanton*, 43 FR at 27,617.

According to California statute, “[n]o person other than a physician . . . shall write or issue a prescription.” Cal. Health & Safety Code § 11150 (West 2020). Further, “physician,” as defined by California statute, is a person who is “licensed to practice” in California. *Id.* at § 11024.

Here, the undisputed evidence in the record is that Registrant currently lacks authority to practice medicine in California. As already discussed, a physician must be a licensed practitioner to dispense a controlled substance in California. Thus, because Registrant lacks authority to practice medicine in California and, therefore, is not authorized to handle controlled substances in California, Registrant is not eligible to maintain a DEA registration. Accordingly, I will order that Registrant’s DEA registration be revoked.

**Order**

Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 824(a), I hereby revoke DEA Certificate of Registration No. AS6936201 issued to Frederick M. Silvers, M.D. Further, pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 823(f), I hereby deny any pending application of Frederick M. Silvers, M.D. to renew or modify this registration, as well as any pending application of Frederick M. Silvers, M.D. for registration in California. This Order is effective August 27, 2020.

**Timothy J. Shea,**

*Acting Administrator.*

[FR Doc. 2020–16343 Filed 7–27–20; 8:45 am]

**BILLING CODE 4410–09–P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA–686]

**Bulk Manufacturer of Controlled Substances Application: Ampac Fine Chemicals LLC**

*Correction*

Notice document 2020–16104, appearing on page 44924 in the issue of Friday, July 24th, 2020, was published as a duplicate of notice document 2020–16104 appearing on pages 44924–44925, and is withdrawn. Notice document 2020–16100, which should have

published Friday, July 24, 2020, is republished elsewhere in this issue.

[FR Doc. C1–2020–16104 Filed 7–27–20; 8:45 am]

**BILLING CODE 1301–00–D**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA–683]

**Bulk Manufacturer of Controlled Substances Application: AMPAC Fine Chemicals Virginia, LLC**

**Editorial Note:** Notice document 2020–16100, which should have published Friday, July 24, 2020, did not appear in that issue. We are republishing it here in its entirety.

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before September 28, 2020.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on March 16, 2020, AMPAC Fine Chemicals Virginia, LLC, 2820 North Normandy Drive, Petersburg, Virginia 23805–2380, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substances:

Controlled substance	Drug code	Schedule
Methylphenidate .....	1724	II
Levomethorphan .....	9210	II
Levorphanol .....	9220	II
Morphine .....	9300	II
Thebaine .....	9333	II
Noroxymorphone .....	9668	II
Tapentadol .....	9780	II

The company plans to manufacture the above-listed controlled substances in bulk for distribution to its customers. No other activities for these drug codes are authorized for this registration.

**William T. McDermott,**

*Assistant Administrator.*

[FR Doc. R1–2020–16100 Filed 7–27–20; 8:45 am]

**BILLING CODE 1301–00–D**

**DEPARTMENT OF JUSTICE**

**Notice of Lodging of Proposed Consent Decree Under the Clean Water Act**

On July 21, 2020, the Department of Justice lodged a proposed consent decree with the United States District Court for the District of Hawaii in the lawsuit entitled *United States v. Pacific Energy South West Pacific, Ltd.*, Civil Action No. 20–CV–322.

The United States filed this lawsuit under the Clean Water Act. The United States’ complaint seeks injunctive relief and civil penalties for violations of a National Pollutant Discharge Elimination System permit, violations of an administrative order issued by the United States Environmental Protection Agency, and unpermitted discharges of pollutants to waters of the United States at the American Samoa Terminal, a fuel terminal that the defendant Pacific Energy South West Pacific, Ltd., operates in Pago Pago, American Samoa. The consent decree requires the defendant to perform injunctive relief and pay a \$300,000 civil penalty.

The publication of this notice opens a period for public comment on the consent decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to *United States v. Pacific Energy South West Pacific, Ltd.*, D.J. Ref. No. 90–5–1–1–12086. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail:

To submit comments:	Send them to:
By email .....	<i>pubcomment-ees.enrd@usdoj.gov.</i>
By mail .....	Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611.

During the public comment period, the consent decree may be examined and downloaded at this Justice Department website: <https://www.justice.gov/enrd/consent-decrees>. We will provide a paper copy of the consent decree upon written request and payment of reproduction costs. Please mail your request and payment to: Consent Decree Library, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611.

Please enclose a check or money order for \$11.50 (25 cents per page

reproduction cost) payable to the United States Treasury.

**Henry Friedman,**

*Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.*

[FR Doc. 2020-16299 Filed 7-27-20; 8:45 am]

**BILLING CODE 4410-15-P**

**NATIONAL CREDIT UNION ADMINISTRATION**

**Sunshine Act Meeting**

**SUMMARY:** Due to the COVID-19 Pandemic, the meeting will be open to the public via live webcast only. Visit the agency's homepage ([www.ncua.gov](http://www.ncua.gov)) and access the provided webcast link.

**DATES:** 10 a.m., Thursday, July 30, 2020.

**STATUS:** This meeting will be open to the public.

**MATTERS TO BE CONSIDERED:**

1. NCUA Rules and Regulations, Chartering and Field of Membership.
2. NCUA Rules and Regulations, Transition to CECL Methodology.
3. NCUA Rules and Regulations, Fees Paid By Federal Credit Unions.
4. Request for Comment, Overhead Transfer Rate and Operating Fee Methodologies.
5. Board Briefing, 2020 Mid-Session Budget.

**CONTACT PERSON FOR MORE INFORMATION:** Gerard Poliquin, Secretary of the Board, Telephone: 703-518-6304.

**Gerard Poliquin,**

*Secretary of the Board.*

[FR Doc. 2020-16366 Filed 7-24-20; 11:15 am]

**BILLING CODE 7535-01-P**

**NUCLEAR REGULATORY COMMISSION**

**Advisory Committee on the Medical Uses of Isotopes: Meeting Notice**

**AGENCY:** U.S. Nuclear Regulatory Commission.

**ACTION:** Notice of meeting.

**SUMMARY:** The U.S. Nuclear Regulatory Commission (NRC) will convene a meeting of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on September 21-22, 2020. A sample of agenda items to be discussed during the public session includes: A discussion of the ACMUI's review and analysis of medical events from fiscal year 2019; a discussion of the ACMUI's review and analysis of non-medical events from fiscal year 2019; a discussion on the U.S. Food and Drug Administration's

regulatory process for the development of drugs and devices; an update on the NRC's Phase 2 revision of Regulatory Guide 8.39, "Release of Patients Administered Radioactive Material"; and an update on the activities of the NRC's Medical Radiation Safety Team. The agenda is subject to change. The current agenda and any updates will be available on the ACMUI's Meetings and Related Documents web page at <https://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2020.html> or by emailing Ms. Kellee Jamerson at the contact information below.

**Purpose:** Discuss issues related to 10 CFR part 35 Medical Use of Byproduct Material.

**Date and Time for Open Sessions:** September 21, 2020, from 10 a.m. to 2 p.m. and September 22, 2020, from 12:15 p.m. to 1:45 p.m. Eastern Standard Time (EST).

Date	Webinar information
September 21, 2020.	Link: <a href="https://usnrc.webex.com">https://usnrc.webex.com</a> . Event number: 199 744 7681.
September 22, 2020.	Link: <a href="https://usnrc.webex.com">https://usnrc.webex.com</a> . Event number: 199 319 2198.

**Date and Time for Closed Session:** September 22, 2020, from 10 a.m. to 12 p.m. EST. This session will be closed to conduct the ACMUI's required annual training.

**Public Participation:** The meeting will be held as a webinar using the WebEx meeting platform. Any member of the public who wishes to participate in any open sessions of this meeting should register in advance of the meeting by visiting the link and entering the event number(s) provided above. Upon successful registration, a confirmation email will be generated providing the telephone bridge line and a link to join the webinar on the day of the meeting. Members of the public should also monitor the NRC's Public Meeting Schedule at <https://www.nrc.gov/pmns/mtg> for any meeting updates. If there are any questions regarding the meeting, persons should contact Ms. Jamerson using the information below.

**Contact Information:** Ms. Kellee Jamerson, email: [Kellee.Jamerson@nrc.gov](mailto:Kellee.Jamerson@nrc.gov), telephone: 301-415-7408.

**Conduct of the Meeting**

Darlene F. Metter, M.D. will chair the meeting. Dr. Metter will conduct the meeting in a manner that will facilitate the orderly conduct of business. The following procedures apply to public participation in the meeting:

1. Persons who wish to provide a written statement should submit an electronic copy to Ms. Jamerson using the contact information listed above. All submittals must be received by the close of business on September 15, 2020, three business days before the meeting, and must pertain to the topics on the agenda for the meeting.

2. Questions and comments from members of the public will be permitted during the meeting, at the discretion of the Chairman.

3. The draft transcript and meeting summary will be available on ACMUI's website <https://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2020.html> on or about November 6, 2020.

4. Persons who require special services, such as those for the hearing impaired, should notify Ms. Jamerson of their planned participation.

This meeting will be held in accordance with the Atomic Energy Act of 1954, as amended (primarily Section 161a); the Federal Advisory Committee Act (5 U.S.C. App); and the Commission's regulations in title 10 of the *Code of Federal Regulations*, Part 7.

Dated at Rockville, Maryland, this 23rd day of July, 2020.

For the U.S. Nuclear Regulatory Commission.

**Russell E. Chazell,**

*Federal Advisory Committee Management Officer.*

[FR Doc. 2020-16290 Filed 7-27-20; 8:45 am]

**BILLING CODE 7590-01-P**

**NUCLEAR REGULATORY COMMISSION**

[NRC-2020-0168]

**Biweekly Notice; Applications and Amendments to Facility Operating Licenses and Combined Licenses Involving No Significant Hazards Considerations**

**AGENCY:** Nuclear Regulatory Commission.

**ACTION:** Biweekly notice.

**SUMMARY:** Pursuant to section 189.a.(2) of the Atomic Energy Act of 1954, as amended (the Act), the U.S. Nuclear Regulatory Commission (NRC) is publishing this regular biweekly notice. The Act requires the Commission to publish notice of any amendments issued, or proposed to be issued, and grants the Commission the authority to issue and make immediately effective any amendment to an operating license or combined license, as applicable, upon a determination by the